For the Inventor, By the Inventor

Enter assignee name

Melville, NY, United States of America

Osi Pharmaceuticals, Inc.

USPTO Granted Patents = 118

% Expired Patents = 51.7

CIPO Patents = 1

EPO Patents = 22

Forward Citations = 949

Loading Chart...

Loading Chart...

186 inventors (with patents filed for the assignee):

Andrew Philip Crew (28 out of 78 patents)

Arlindo Lucas Castelhano (25 out of 44 patents)

Mark Joseph Mulvihill (24 out of 25 patents)

4. An-Hu Li (21 out of 26 patents)

5. Arno G Steinig (15 out of 15 patents)

6. Douglas S Werner (14 out of 20 patents)

7. Bryan McKibben (14 out of 15 patents)

8. David James Witter (13 out of 50 patents)

9. Bijoy Panicker (13 out of 28 patents)

10. Hanqing Dong (12 out of 57 patents)

11. Jing Wang (12 out of 58 patents)

12. Radoslaw Laufer (11 out of 30 patents)

13. Xin Chen (11 out of 17 patents)

14. Lee Daniel Arnold (11 out of 40 patents)

15. Ayako Honda (10 out of 16 patents)

Core Competencies:

Kinase Inhibitors

Isothiazole Derivatives

Combination Therapy

Biological Markers

mTOR Inhibitors

EGFR Inhibitors

Amino Pyrimidine Compounds

Tumor Cell Inhibition

Pyrrolo Compounds

Fused Bicyclic Inhibitors

EMT Gene Signatures

Integrin Antagonists

118 patents: Sort by Forward Citations

1. 11833149 - Pulse dosing regimen and methods of treatment (2023-12-05),

2. 11253520 - Pulse dosing regimen and methods of treatment (2022-02-22),

3. 10583142 - Pulse dosing regimen and methods of treatment (2020-03-10),

4. 9896730 - Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment (2018-02-20),

5. 9371298 - Processes for the preparation of isothiazole derivatives (2016-06-21),

6. 9351974 - Substituted pteridinones for the treatment of cancer (2016-05-31),

7. 9244058 - Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors (2016-01-26),

8. 9133224 - Macrocyclic kinase inhibitors (2015-09-15),

9. 9096624 - Amino pyrimidine anticancer compounds (2015-08-04),

10. 8796455 - Fused bicyclic mTOR inhibitors (2014-08-05),

11. 8735405 - 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors (2014-05-27),

12. 8653268 - 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors (2014-02-18),

13. 8642834 - Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation (2014-02-04),

14. 8592448 - Substituted pyrrolo[2,3-b]-pyridines and -pyrazines (2013-11-26),

15. 8586546 - Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors (2013-11-19),

Company Overview

Osi Pharmaceuticals, Inc., based in Melville, NY, specializes in the development of innovative cancer therapeutics. The company focuses on advanced treatment modalities, particularly in the realm of kinase inhibitors and mTOR inhibitors, which play a crucial role in targeting specific pathways involved in tumor growth. Osi Pharmaceuticals is also engaged in research surrounding isothiazole derivatives and amino pyrimidine compounds, aiming to enhance the efficacy of combination therapies and improve patient outcomes through the identification of biological markers.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

118 Patents

#7 in Melville, NY

#201 in New York

#3,269 in US

#6,746 in the World

Melville, NY, United States of America

Osi Pharmaceuticals, Inc.

Forward Citations = 949

186 inventors:

Andrew Philip Crew (28 out of 78 patents)

Arlindo Lucas Castelhano (25 out of 44 patents)

Mark Joseph Mulvihill (24 out of 25 patents)

4. An-Hu Li (21 out of 26 patents)

5. Arno G Steinig (15 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Osi Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/osi-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…